ClinicalTrialsFinder
RecruitingNot ApplicableNCT07231484

Effects of Grape Consumption on the Immune-Gut Axis in Obesity

Effects of Grape Consumption on Immune and Gut Health in the Setting of Obesity

Sponsor

University of Missouri-Columbia

Enrollment

50 participants

Start Date

Dec 19, 2025

Study Type

INTERVENTIONAL

Conditions

Obesity &Amp; Overweight

Summary

This study is investigating the benefits of whole freeze-dried grape powder consumption on the immune-gut axis in adults with obesity.

Eligibility

Min Age: 30 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Freeze-dried grape powder and Placebo powder for people with obesity & overweight. The study is currently recruiting participants at 1 location. People eligible for this study include aged 30 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERFreeze-dried grape powder

48 g/day oral consumption during the 4-week active period.

OTHERPlacebo powder

Isocaloric placebo matched to grape powder; oral consumption during the 4-week active period.

Locations(1)

University of Missouri-Columbia

Columbia, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07231484

Related Trials

Sanctuary Farm Prescription in Adolescents

NCT072185883 locations

Training App for Inhibitory Control Towards Food

NCT070759521 location

A Prospective Randomnised Controlled Trial Comparing Overall Patient Compliance in a Bariatric Surgical Pathway Using the Standard Versus a More Intensified and Interactive Version of the "Get Ready" Smartphone Application.

NCT072973421 location

UBT251 Injection Phase II Clinical Study (CKD)

NCT071343351 location

Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

NCT072457711 location